Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H16NO.Br |
Molecular Weight | 246.144 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC[N+](C)(C)C1=CC=CC(O)=C1
InChI
InChIKey=CAEPIUXAUPYIIJ-UHFFFAOYSA-N
InChI=1S/C10H15NO.BrH/c1-4-11(2,3)9-6-5-7-10(12)8-9;/h5-8H,4H2,1-3H3;1H
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.rxlist.com/enlon-drug.htm
Sources: http://www.rxlist.com/enlon-drug.htm
Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Originator
Sources: https://www.google.com/patents/US2647924
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
|||
Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21397501 |
|||
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8109771 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date1985 |
|||
Preventing | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date1985 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
56.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Myasthenia syndrome during penicillamine treatment. | 1975 Jun 28 |
|
Determination of inhibitors' potency (IC50) by a direct high-performance liquid chromatographic method on an immobilised acetylcholinesterase column. | 2001 Apr 5 |
|
[Myasthenia gravis is improved temporarily at postburn period]. | 2001 May |
|
[Giant-cell myocarditis without a symptom of heart failure seen in a patient with myasthenia gravis and concurrent Hashimoto's disease]. | 2001 Nov |
|
Clinical, electrophysiological and immunological remissions after thymectomy in myasthenia gravis. | 2002 Apr |
|
Effects of the anticholinesterase edrophonium on spectral analysis of heart rate and blood pressure variability in humans. | 2002 Jan |
|
Noncardiac chest pain. | 2002 Jan |
|
[Myasthenia gravis]. | 2002 Jan 1 |
|
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. | 2003 |
|
[Premonitory depression]. | 2003 |
|
Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium. | 2003 Nov |
|
Clinical and neurophysiological characteristics of congenital myasthenic syndromes presenting in early infancy. | 2004 Jan |
|
Immunological and electrophysiological investigations of severe ptosis after bone marrow transplantation. | 2004 Sep |
|
Advances in the diagnosis of neuromuscular junction disorders. | 2005 Aug |
|
Postinfectious myasthenia gravis: report of two children. | 2005 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.rxlist.com/enlon-drug.htm
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8
Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated.
Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions.
For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:08:07 GMT 2025
by
admin
on
Mon Mar 31 19:08:07 GMT 2025
|
Record UNII |
KX008093VW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9336
Created by
admin on Mon Mar 31 19:08:07 GMT 2025 , Edited by admin on Mon Mar 31 19:08:07 GMT 2025
|
PRIMARY | |||
|
m4834
Created by
admin on Mon Mar 31 19:08:07 GMT 2025 , Edited by admin on Mon Mar 31 19:08:07 GMT 2025
|
PRIMARY | Merck Index | ||
|
DBSALT002779
Created by
admin on Mon Mar 31 19:08:07 GMT 2025 , Edited by admin on Mon Mar 31 19:08:07 GMT 2025
|
PRIMARY | |||
|
302-83-0
Created by
admin on Mon Mar 31 19:08:07 GMT 2025 , Edited by admin on Mon Mar 31 19:08:07 GMT 2025
|
PRIMARY | |||
|
KX008093VW
Created by
admin on Mon Mar 31 19:08:07 GMT 2025 , Edited by admin on Mon Mar 31 19:08:07 GMT 2025
|
PRIMARY | |||
|
DTXSID00952590
Created by
admin on Mon Mar 31 19:08:07 GMT 2025 , Edited by admin on Mon Mar 31 19:08:07 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |